Image design: Philip Patenall

Free Article Series: Peripheral Neuropathies

Latest Reviews

  • Essay |

    To coincide with the 200th anniversary of the publication of An Essay on the Shaking Palsy by James Parkinson, Goedert and Compston explore the origins of the eponym 'Parkinson's disease'. Although Jean-Martin Charcot is often credited with introducing the name in the 1880s, it can actually be traced back to an 1865 publication by William Rutherford Sanders.

    • Michel Goedert
    •  & Alastair Compston
  • Review |

    Two decades after antisense oligonucleotides (ASOs) were initially identified as agents capable of modulating RNA processing and protein expression, the first antisense oligonucleotide (ASO) therapies have now been approved for the treatment of neurological disease. Here, Rinaldi and Wood discuss our current understanding of ASO pharmacology, and the future prospects for ASO-mediated treatment of neurological disease

    • Carlo Rinaldi
    •  & Matthew J. A. Wood
  • Review |

    Idiopathic rapid eye movement (REM) sleep behavioural disorder (RBD) is now recognized as an early marker of α-synucleinopathies. Here, Högl and colleagues review potential biomarkers for RBD and summarize the evidence for a prodromal stage, which might enable disease-modifying intervention. In light of these advances, they reconceptualize idiopathic RBD as isolated RBD.

    • Birgit Högl
    • , Ambra Stefani
    •  & Aleksandar Videnovic
  • Review |

    Inadequate remyelination is central to degeneration and disability in patients with multiple sclerosis (MS); however, all currently approved therapies for MS are primarily immunomodulatory. Here, Martin Stangel and colleagues review our current knowledge of remyelination in MS, discuss results from clinical trials of remyelination-enhancing therapies, and evaluate the opportunities for future regenerative treatments.

    • Martin Stangel
    • , Tanja Kuhlmann
    • , Paul M. Matthews
    •  & Trevor J. Kilpatrick
  • Review |

    The causes of migraine remain unknown despite the high prevalence and societal burden of this disorder. Here, the authors highlight how advances in imaging and genetic studies of migraine provide insights into the underlying mechanisms of this disorder; furthermore, they discuss the potential for genetic and imaging biomarkers to improve our ability to prevent and treat migraine attacks.

    • Dale R. Nyholt
    • , David Borsook
    •  & Lyn R. Griffiths
  • Opinion |

    The development of immune checkpoint inhibitors (ICIs) has revolutionized cancer immunotherapy, but these agents carry a high risk of immune-related adverse events. Here, the authors introduce the mechanisms of action of ICIs and review their adverse effects on the CNS, which result in conditions such as paraneoplastic neurological syndromes and multiple sclerosis.

    • Lidia M. Yshii
    • , Reinhard Hohlfeld
    •  & Roland S. Liblau

News & Comment

Natureevents Directory